abstract |
The present invention relates to compounds of formula (I) Compounds of formula I may disrupt BCL-2 interactions with BH3 domain containing proteins. This disturbance of the interaction may restore anti-apoptotic function of BCL-2 in cancer cells and tumor tissues expressing BCL-2. The invention further provides methods of making the compounds of the invention, pharmaceutical formulations comprising such compounds, and methods of using such compounds in the treatment of cancerous diseases. (I) Wherein R 1 , R 2 , R 3 and R 4 are as defined in the description of the invention. |